Curative Biotechnology Company Insiders

Curative Biotechnology Management Team Effectiveness

The company has return on total asset (ROA) of (0.5178) % which means that it has lost $0.5178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9828) %, meaning that it created substantial loss on money invested by shareholders. Curative Biotechnology's management efficiency ratios could be used to measure how well Curative Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Curative Biotechnology's Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 1.94 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (4.68). At this time, Curative Biotechnology's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 21.9 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.3 M in 2024. Common Stock Shares Outstanding is likely to drop to about 461 M in 2024. Net Loss is likely to gain to about (16.1 M) in 2024

Curative Biotechnology Workforce Comparison

Curative Biotechnology Benchmark Summation

Curative Biotechnology Notable Stakeholders

The success or failure of an entity such as Curative Biotechnology often depends on how effective the management is. Curative Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Curative management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Curative management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Curative Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Curative Biotechnology. Check Curative Biotechnology's Beneish M Score to see the likelihood of Curative Biotechnology's management manipulating its earnings.

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.